NCT07370142Completed
Sphenopalatine Ganglion Pulsed Radiofrequency Treatment Outcomes
Clinical Outcomes of Sphenopalatine Ganglion Pulsed Radiofrequency in Refractory Craniofacial Pain Syndromes: A Prospective Clinical Study
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
Purpose of the Study: This study aims to evaluate the clinical effectiveness and long-term outcomes of "Sphenopalatine Ganglion (SPG) Pulsed Radiofrequency (PRF)" treatment in patients with chronic headaches and facial pain. The SPG is a major neural junction for craniofacial pain signaling. PRF is a safe, minimally invasive technique that modulates pain transmission without causing thermal damage to the nerve tissue. Methodology: The study will include 55 volunteer patients at the Ankara Bilkent City Hospital Algology Clinic who are unresponsive to medical treatments. Patients will undergo the standard "fluoroscopy-guided infrazygomatic approach." Pain intensity (VAS), quality of life, patient satisfaction, and changes in analgesic consumption will be recorded at baseline and during follow-up visits at 1 week, 1 month, 3 months, and 6 months post-procedure using various clinical parameters. Expected Benefits and Risks: The research intends to provide evidence regarding the 6-month long-term impact of this intervention on pain scores and patient well-being. Since the study follows routine clinical practices, it poses no additional risks to participants and aims to optimize future treatment strategies.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 55 (actual)
- First submitted
- 19 Jan 2026
- Start date
- 20 Mar 2025
- Primary completion date
- 1 Oct 2025
- Lead sponsor
- Ankara City Hospital Bilkent
- Diseases
- Migraine
- NCT number
- NCT07370142
What you commit to
- Study type: Interventional
- Participants enrolled: 55
- From 20 Mar 2025 to the primary completion date, 1 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous surgical intervention involving the sphenopalatine ganglion
Other illness
- Systemic infection or local skin infection at the needle insertion site
- Known coagulopathy or bleeding disorders
- Presence of a cardiac pacemaker or implantable cardioverter-defibrillator (ICD)
- Severe psychiatric or cognitive disorders preventing reliable pain assessment or follow-up
Other
- Presence of an intracranial mass or significant anatomical distortion in the pterygopalatine fossa region
- Pregnancy or breastfeeding
- Hemodynamic instability
- Refusal to participate in the study or undergo the procedure
Who the study is looking for
- Patients aged 18 years and older (no upper age limit)
- Patients diagnosed with refractory chronic headache (including cluster headache, migraine, paroxysmal hemicrania, hemicrania continua, SUNCT, or SUNA) or chronic orofacial pain / trigeminal neuralgia
- Pain duration of at least 3 months
- Pain intensity score (VAS or NRS) \> 3 out of 10
- Patients unresponsive to conservative medical treatments
- Patients scheduled for sphenopalatine ganglion (SPG) pulsed radiofrequency (PRF) treatment as part of routine clinical care
- Ability and willingness to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ankara Bilkent City Hospital Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.